Methamphetamine neurotoxicity: Necrotic and apoptotic mechanisms and relevance to human abuse and treatment

Brain Research Reviews

Volumn 36, Issue 1, 2001, Pages 1-22

  Davidson, Colin ^a   Gow, Andrew J ^a   Lee, Tong H ^a   Ellinwood, Everett H ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dopamine; Dosing regimen; Hyperthermia; Mitochondria; Reactive species; Treatments

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); ALPHA TOCOPHEROL; AMFONELIC ACID; ANTIOXIDANT; ASCORBIC ACID; BROMOCRIPTINE; CITALOPRAM; DISULFIRAM; DIZOCILPINE; DOPAMINE; DOPAMINE TRANSPORTER; ENKEPHALIN[2 DEXTRO ALANINE 5 DEXTRO LEUCINE]; FLUOXETINE; INDATRALINE; KETAMINE; METHAMPHETAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NITRIC OXIDE SYNTHASE; NITROGEN; PRAMIPEXOLE; PROTEIN C FOS; QUINPIROLE; REACTIVE OXYGEN METABOLITE; SAPROPTERIN; SELEGILINE; SEROTONIN TRANSPORTER; SUPEROXIDE DISMUTASE; UNINDEXED DRUG; VANOXERINE;

ACUTE TOXICITY; ANTIOXIDANT ACTIVITY; APATHY; APOPTOSIS; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG MECHANISM; ELECTRON TRANSPORT; HUMAN; HYPERTHERMIA; KNOCKOUT MOUSE; MEMBRANE POTENTIAL; MENTAL DISEASE; MITOCHONDRIAL MEMBRANE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; SUBSTANCE ABUSE; TRANSGENIC MOUSE; WITHDRAWAL SYNDROME;

AMPHETAMINE-RELATED DISORDERS; ANIMALS; APOPTOSIS; CENTRAL NERVOUS SYSTEM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HUMANS; METHAMPHETAMINE; NECROSIS; NERVE DEGENERATION; NEUROTOXINS; PARKINSON DISEASE;

EID: 0034882387     PISSN: 01650173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-0173(01)00054-6     Document Type: Review

References (229)

1. Iron metabolism
2. Methamphetamine-induced hyperthermia and dopaminergic neurotoxicity in mice: Pharmacological profile of protective and nonprotective agents
3. Low environmental temperatures or pharmacologic agents that produce hypothermia decrease methamphetamine neurotoxicity in mice
4. Methamphetamine-induced dopaminergic toxicity in mice. Role of environmental temperature and pharmacological agent
5. Neuroprotective role of melatonin in methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity
6. Amphetamine metabolism in amphetamine psychosis
7. Differential diagnosis of parkinsonism with [18F] fluorodeoxyglucose and PET
8. Structural features amphetamine neurotoxicity in the brain
9. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine
10. Reliability of medial temporal lobe volume measurements using reformatted 3D images
11. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide
12. Nitric oxide, superoxide, and peroxynitrite: The good, the bad, and ugly
13. Nitric oxide-mediated mitochondrial damage in the brain: Mechanisms and implications for neurodegenerative diseases
14. Regulation of mitochondrial respiration by oxygen and nitric oxide
15. The influence of environmental temperature on the transient effects of methamphetamine on dopamine levels and dopamine release in rat striatum
16. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats
17. Further studies if the role of hyperthermia in methamphetamine neurotoxicity
18. Methamphetamine and amphetamine neurotoxicity
19. Nitric oxide regulation of methamphetamine-induced dopamine release in caudate/putamen
20. Neuronal degeneration in rat forebrain resulting from d-amphetamine induced convulsions is dependent upon severity and age
21. Neuronal degeneration in the limbic system of weanling rats exposed to saline, hyperthermia or D-amphetamine
22. Methamphetamine selectively damages dopaminergic innervation to the nucleus accumbens core while sparing the shell
23. Dual serotonin (5-HT) projections to the nucleus accumbens core and shell: Relation of the 5-HT transporter to the amphetamine-induced neurotoxicity
24. Do NMDA antagonists prevent neuronal injury? No
25. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species
26. High-dose methamphetamine treatment alters presynaptic gaba and glutamate immunoreactivity
27. Central administration of methamphetamine synergizes with metabolic inhibition to deplete striatal monoamines
28. Attenuation of methamphetamine-induced neurotoxicity in copper/zinc superoxide dismutase transgenic mice
29. Free radicals and the pathobiology of brain dopamine systems
30. Effect of 7-Nitroindazole on body temperature and methamphetamine-induced dopamine toxicity
31. Ontogeny of methamphetamine-induced neurotoxicity and associated hyperthermic response
32. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram
33. Recovery of presynaptic dopaminergic functioning in rats treated with neurotoxic doses of methamphetamine
34. Attenuation and recovery of evoked overflow of striatal serotonin in rats treated with neurotoxic dose of methamphetamine
35. Pramipexole reduces reactive oxygen species production in vivo and in vitro and inhibits the mitochondrial permeability transition produced by the Parkinsonian neurotoxin methylpyridinium ion
36. An evaluation of the role of mitochondria in neurodegenerative diseases: Mitochondrial mutations and oxidative pathology, protective nuclear responses, and cell death in neurodegeneration
37. The respiratory chain and oxidative phosphorylation
38. Differential neurotoxicity induced by L-DOPA and dopamine in cultured striatal neurons
39. Relevance of pharmacokinetic parameters in animal models of methamphetamine abuse
40. Time course of brain temperature and caudate/putamen microdialysate levels of amphetamine and dopamine in rats after multiple doses of d-amphetamine
41. Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide
42. MK-801 reduces cerebral ischemia injury by inducing hypothermia
43. Methamphetamine neurotoxicity involves vacuolation of endocytic organelles and dopamine-dependent intracellular oxidative stress
44. Reactive oxygen intermediates target CC(A/T)6GG sequences to mediate activation of the early growth response 1 transcription factor gene by ionizing radiation
45. Protection against methamphetamine-induced neurotoxicity to neostriatal dopaminergic neurons by adenosine receptor activation
46. Peroxynitrite: A putative cytotoxin
47. Induction of cyctine transport and other stress proteins by disulfiram: Effects on glutathione levels in cultured cells
48. Null mutation of c-fos causes exacerbation of methamphetamine-induced neurotoxicity
49. Methamphetamine-induced neuronal damage: A possible role for free radicals
50. Functional consequences following methamphetamine-induced neuronal damage
51. + and dopamine uptake by striatal synaptosomes
52. Role of nitric oxide in methamphetamine neurotoxicity: Protection by 7-nitroindazole, an inhibitor of neuronal nitric oxide synthase
53. Heat shock protein synthesis and cytoskeletal rearrangements occur independently of intracellular free calcium increases Drosophila cells and tissues
54. Modulation of the neurotoxic effects of methamphetamine by the selective kappa-opioid receptor agonist U69593
55. Neuronal nitric oxide synthase activation and peroxynitrite formation in ischaemic stroke liked to neural damage
56. Chronic amphetamine use and abuse
57. Olfactory forebrain seizures induced by methamphetamine and disulfiram
58. Long-term changes in dopaminergic innervation of caudate nucleus after continuous amphetamine administration
59. Continuous amphetamine and cocaine have similar neurotoxic effects in lateral habenular nucleus and fasciculus retroflexus
60. The neurotoxic effects of continuous cocaine and amphetamine in Habenula: Implications for the substrates of psychosis
61. Evidence for long-term neurotoxicity associated with methamphetamine abuse
62. Central nervous system cytopathological changes in cats with chronic methedrine intoxication
63. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine
64. Role of hyperthermia in the mechanism of protection against toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan
65. Effects of glutamate antagonists on methamphetamine and 3,4-methylenedioxymethamphetamine-induced striatal dopamine release in vivo
66. Tolerance development to chronic methamphetamine intoxication in the rhesus monkey
67. Differential effects of psychostimulant agents on dopaminergic and serotonergic transporter function
68. Long-term monoamine depletion, differential recovery and subtle behavioral impairment following methamphetamine-induced neurotoxicity
69. Role of dopamine transporter in methamphetamine-induced neurotoxicity: Evidence from mice lacking the transporter
70. Increased methamphetamine neurotoxicity in heterozygous vesicular monoamine transporter 2 knockout mice
71. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice
72. Experimental studies of mechanisms involved in methods demonstrating axonal and terminal degeneration
73. Neuronal sparing and behavioral effects of the antiapoptotic drug, (-) deprenyl, following kainic acid administration
74. MK-801 attenuates the methamphetamine induced in tryptophan hydroxylase activity
75. Agonists of A1 and A2A adenosine receptors attenuate methamphetamine-induced overflow of dopamine in rat striatum
76. Protein nitration in Parkinson's disease
77. Carbon dioxide enhancement of peroxynitrite-mediated protein tyrosine nitration
78. Nitric oxide and peroxynitrite-mediated pulmonary cell death
79. Pathophysiological reactivities of nitric oxide
80. Two distinct mechanisms of nitric oxide-mediated neuronal cell death show thiol dependency
81. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine and related compounds toward C-1300 neuroblastoma cells in vitro
82. Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons
83. c-jun and Egr-1 participate in DNA synthesis and cell survival in response to ionizing radiation exposure
84. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections
85. [D-Ala2, D-Leu5] enkephalin blocks the methamphetamine-induced c-fos mRNA increase in mouse striatum
86. Nitric oxide, mitochondria and neurological disease
87. Inducible and constitutive transcription factors in the mammalian nervous system: Control of gene expression by Jun, Fos and Krox, and CREB/ATF proteins
88. Effects of dizocilpine (MK-801) on flash-evoked potentials, body temperature, and locomotor activity of hooded rats
89. Autoradiographic evidence for methamphetamine-induced striatal dopaminergic loss in mouse brain; attenuation in CuZu-superoxide dismutase transgenic mice
90. Melatonin attenuates methamphetamine-induced toxic effects on dopamine and serotonin terminals in mouse brain
91. Superoxide radicals are mediators of the effects of methamphetamine on Zif268 (Egr-l, NCFI-A) in the brain: Evidence from using CuZn superoxide dismutase transgenic mice
92. Iron metabolism and Parkinson's disease
93. Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in the rat brain
94. Nicotinamide attenuates methamphetamine-induced striatal dopamine depletion in rats
95. Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity
96. Selenium, an antioxidant, attenuates methamphetamine-induced dopaminergic toxicity and peroxynitrite generation
97. Peripherally administered tetrahydrobiopterin increases in vivo tryptophan hydroxylase activity in the striatum after transplantation of fetal ventral mesencephalon in six hydroxydopamine lesioned rats
98. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo
99. Resistance of neuronal nitric oxide synthase-deficient mice to methamphetamine-induced dopaminergic neurotoxicity
100. Amphetamine (or amphetamine-like)-related disorders
101. Methamphetamine-induced changes in antioxidant enzymes and lipid peroxidation in copper/zinc-superoxide dismutase transgenic mice
102. Tryptamine-4,5-dione, a putative endotoxic metabolite of the superoxide-mediated oxidation of serotonin, is a mitochondrial toxin: Possible implications in neurodegenerative brain disorders
103. Effect of MK-801 on the decrease in tryptophan hydroxylase induced by methamphetamine and its methylenedioxy analog
104. Pleiotropic effects of a null mutation in the c-fos proto-oncogene
105. Death in amphetamine users: Causes and rates
106. Disulfiram and diethyldithiocarbamate are competitive inhibitors at the peripheral benzodiazepine receptor
107. The nitric oxide/superoxide assay. Insights into the biological chemistry of the NO/O-2 interaction
108. Protection of methamphetamine nigrostriatal toxicity by dietary selenium
109. Methamphetamine-induced neurotoxicity: Structure activity relationships
110. 11C] dihydrotetrabenazine by dynamic PET: Measurement of vesicular monoamine transporter
111. Age-dependent differential responses of monoaminergic systems to high doses of methamphetamine
112. Use and abuse of amphetamine in Japan
113. Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide
114. Enhancement of neuronal survival by 6R-tetrahydrobiopterin
115. The serotoninergic innervation of cerebral cortex: Different classes of axon terminals arise from dorsal and median raphe nuclei
116. Allosteric regulation of neuronal nitric oxide synthase by tetrahydrobiopterin and suppression of auto-damaging superoxide
117. Amphetamine abuse: Pattern and effects of high doses taken intravenously
118. The inflammatory reaction following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine intoxication in mouse
119. A tutorial on the diffusibility and reactivity of free nitric oxide
120. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure
121. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: Evidence against a role for extracellular dopamine
122. MK-801, but not drugs acting at strychnine-insensitive glycine receptors, attenuate methamphetamine nigrostriatal toxicity
123. Effect of psychotomimetics and some putative anxiolytics on stress-induced hyperthermia
124. Mitochondrial dysfunction in the pathogenesis of necrotic and apoptotic cell death
125. Identification of jun-B as a third member in human antioxidant response element-nuclear protein complex
126. The regulation of dopamine release from striatum slices by tetrahydrobiopterin and L-arginine-derived nitric oxide
127. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease
128. Dopaminergic mechanisms in idiopathic and drug-induced psychoses
129. Hyperthermia enhances the cytotoxic effects of reactive oxygen species to Chinese hamster cells and bovine endothelial cells in vitro
130. Excitatory amino acids as a final common pathway for neurologic disorders
131. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
132. Effect of disulfiram administration on glutamate uptake by synaptosomes in the rat brain
133. Antioxidant action of soduim diethyldithiocarbanate: Reaction with hydrogen peroxide and superoxide radical
134. Protection by disulfiram and diethyldithiocarbamate against hypoxia-induced lethality in mice
135. Kinetics and mechanism of tetrahydrobiopterin-induced oxidation of nitric oxide
136. 11C]WIN-35,428
137. Rate of cell death in Parkinsonism indicates active neuropathological process
138. Pharmacokinetic and pharmacodynamic analysis of the actions of D-amphetamine and D-methamphetamine on the dopamine terminal
139. 18F]fluoro-L-DOPA-PET studies show partial reversibility of long-term effects of chronic amphetamine in monkeys
140. 18F]fluoro-L-DOPA-PET profiles of long-term vulnerability to chronic amphetamine
141. 11C]WIN 35,428-positron emission tomography studies
142. 11C]WIN 35,428 binding in striatum are reduced by GDNF:PET studies in the Vervet monkey
143. The interactions of MK-801 with the amphetamine analogues D-methamphetamine (D-Meth), 3,4-methylenedioxymethamphetamine (D-MDMA) or D-fenfluramine (D-FEN): Neural damage and neural protection
144. The role of temperature, stress, and other factors in the neurotoxicity of the substituted amphetamines 3,4-methylenedioxymethamphetamine and fenfluramine
145. Involvement of Jun and Fos proteins in regulating transcriptional activation of the human pi class glutathione S-transferase gene in multidrug-resistant MCF7 breast cancer cells
146. Dynamic regulation of NGFI-A (zif268, egr1) gene expression in the striatum
147. The pathogenic role of the NMDA receptor in hyperthermia-induced seizures in developing rats
148. MK-801, a non-competitive antagonist of NMDA receptor prevents methamphetamine-induced decrease of striatal dopamine uptake sites in the rat striatum
149. Mitochondria in neurodegeneration: Bioenergetic function in cell life and death
150. Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin
151. Metabolic inhibition enhances selective toxicity of L-DOPA toward mesencephalic dopamine neurons in vitro
152. Effect of D-amphetamine on the extracellular concentrations of glutamate and dopamine in iprindole-treated rats
153. Methamphetamine neurotoxicity and striatal glutamate release: Comparison to 3,4-methylenedioxymethamphetamine
154. Neurotoxic effects of substituted amphetamine in rats and mice: Challenge to the current dogma
155. MK-801 prevents methamphetamine-induced striatal dopamine damage and reduces extracellular dopamine overflow
156. Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotonergic neurotoxicity produced by methamphetamine in various brain regions
157. Antioxidant enzymes and survival of normal and simian virus 40-transformed mouse embryo cells after hyperthermia
158. Effect of chronic amphetamine administration on central dopaminergic mechanisms in the vervet
159. Antiapoptotic actions of monoamine oxidase B inhibitors
160. Regional differences in the effects of amphetamine withdrawal on dopamine dynamics in the striatum
161. Comparison of the effects of the acute administration of dexoxadrol, levoxadrol, MK-801 and phencyclidine on body temperature in the rat
162. Privileged access to mitochondria of calcium influx through N-methyl-D-aspartate receptors
163. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts
164. Role of quinone-mediated generation of hydroxyl radicals in the induction of glutathione S-transferase gene expression
165. Long-term effects of repeated methylamphetamine administration on monoamine neurons in the rhesus monkey brain
166. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity
167. The effects of amfonelic acid, a dopamine uptake inhibitor, on methamphetamine-induced dopaminergic terminal degeneration and astrocytic response in rat striatum
168. Protective effects of MK-801 on methamphetamine-induced depletion of dopaminergic and serotonergic terminals and striatal astrocytic response: An immunohistochemical study
169. Decreased hyperthermia effect of MK-801 in selectively bred hypercholinergic rats
170. Potentiation by reserpine and tetra-benozine of brain catecholamine depletion by MPTP in the mouse: Evidence for subcellular sequestration as a basis for cellular resistance to the toxicant
171. Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: A regional study
172. Dopamine nerve terminal degeneration produced by high doses of methylamphetamine in the rat brain
173. Further evidence that amphetamine produced long lasting dopamine neurochemical deficits by destroying dopamine nerve fibers
174. Functional consequences of neurotoxic amphetamine exposure
175. Reactive astrocytes: Cellular and molecular cues to biological function
176. Behavioral and biochemical effects of chronic amphetamine treatment in the vervet monkey
177. The long-term effects of neurotoxic doses of methamphetamine on the extracellular concentration of dopamine measured with microdialysis in striatum
178. Neurochemical neutralization of methamphetamine with high affinity nonselective inhibitors of biogenic amine transporters: A pharmacological strategy for treating stimulant abuse
179. Histological and ultrastructural evidence that d-amphetamine causes degeneration in the neostriatum frontal cortex of rats
180. Methamphetamine decreases mouse striatal dopamine transporter activity: Roles of hyperthermia and dopamine
181. Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: Mechanisms of neuroprotective treatment against oxidative stress
182. Role of the serotonin uptake carrier in the neurochemical response to methamphetamine: Effects of citalopram and chloroimipramine
183. Methamphetamine exposure can produce neuronal degeneration in mouse hippocampal remnants
184. Catecholamines and drug-behavior interactions
185. Neurotoxicity of methamphetamine and related drugs
186. Amphetamine: Effects on catecholamine systems and behavior
187. Methamphetamine and methylenedioxymethamphetamine neurotoxicity: Possible mechanisms of cell destruction
188. Methamphetamine-induced neurotoxicity is associated with increased striatal AP-1 DNA-binding activity in mice
189. Nitric oxide is a mediator of methamphetamine (METH)-induced neurotoxicity. In vitro evidence from primary cultures of mesencephalic cells
190. Functional characterization of the human basic fibroblast growth factor gene promoter
191. Role of tetrahydrobiopterin in the function of nitric oxide synthase, and its cytoprotective effect
192. Oxidative stress as a precursor to the irreversible hepatocellular injury caused by hyperthermia
193. Role for excitatory amino acids in methamphetamine-induced dopaminergic toxicity
194. Competitive and noncompetitive antagonist at N-methyl-D-aspartate receptors protect against methamphetamine-induced dopaminergic damage in mice
195. Treatment of mice with methamphetamine produces cell loss in the substantia nigra
196. Role of glutamate in neurodegenerative of dopamine neurons in several animal models of parkinsonism
197. Dopamine turnover and glutathione oxidation: Implications for Parkinson disease
198. Methamphetamine-induced neurotoxicity: Roles for glutamate and dopamine efflux
199. Substrates of energy metabolism attenuate methamphetamine-induced neurotoxicity in striatum
200. 2+ after heat shock
201. Effect of hyperthermia (45 degrees C) on calcium flux in Chinese hamster ovary HA-1 fibroblasts and its potential role in cytotoxicity and heat resistance
202. Glutamate-induced neuron death requires mitochondrial calcium uptake
203. Delta opioid peptide [D-Ala(2),D-Leu(5)] enkephalin promotes cell survival
204. 2 knockout mice: Heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion and enhanced MPTP toxicity
205. Mitochondria in neurodegenerative apoptosis: An opportunity for therapy?
206. Neurodegenerative disorders: The role of peroxynitrite
207. Delta opioid peptide [D-Ala2,D-leu5] enkephalin blocks the long-term loss of dopamine transporters induced by multiple administrations of methamphetamine: Involvement of opioid receptors and reactive oxygen species
208. Reversal by [D-Ala2,D-Leu5] enkephalin of the dopamine transporter loss caused by methamphetamine
209. Differential mechanisms in the effects of disulfiram and diethyldithiocarbamate intoxication on striatal release and vesicular
210. 11C]WIN 35,428 positron emission tomography studies and direct in vitro determinations
211. Deprenyl and the issue of neuroprotection
212. Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers
213. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers
214. Pretreatment with ascorbic acid attenuates the neurotoxic effects of methamphetamine in rats
215. Evaluation of the effects of inhibition of monoamine oxidase and senescence on methamphetamine-induced neuronal damage
216. Intra-striatal infusion of D-amphetamine induces hydroxyl radical formation: Inhibition by MK-801 pretreatment
217. Bone and haematopoietic defects in mice lacking c-fos
218. Role of kainate/AMPA receptors in induction of striatal zif/268 and preprodynorphin mRNA by a single injection of amphetamine
219. Increased expression of monoamine oxidase-B results in enhanced neurite degeneration in methamphetamine-treated PC12 cells
220. MK-801 protection against methamphetamine-induced striatal dopamine terminal injury is associated with attenuated dopamine overflow
221. Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease
222. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users
223. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide
224. Long-term effects of chronic methamphetamine administration in rhesus monkeys
225. Oxidation of serotonin by superoxide radical: Implications to neurodegenerative brain disorders
226. Nuclear factor-kappaB plays an essential role in the late phase of ischemic preconditioning in conscious rabbits
227. The effects of methamphetamine on the production of free radicals and oxidative stress
228. Fatal amphetamine poisoning
229. Striatal dihydroxyphenylalanine decarboxylase and tyrosine hydroxylase protein in idiopathic Parkinson's disease and dominantly inherited olivopontocerebellar atrophy